Concerta (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending

Concerta (Methylphenidate HCl) by Johnson & Johnson: Off-Patent Genericized (AB Competition), 13 AB generics, $504.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN021121 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$504.7M
2024 Medicare Part D Spend$10.5M
2024 Medicaid Spend$494.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.